HC Wainwright Has Optimistic Outlook of XFOR Q1 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities research analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of X4 Pharmaceuticals in a research report issued to clients and investors on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.02) per share for the quarter, up from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.32) EPS, FY2026 earnings at ($0.23) EPS and FY2027 earnings at ($0.16) EPS.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $3.00 target price on shares of X4 Pharmaceuticals in a research report on Wednesday, March 26th.

X4 Pharmaceuticals Trading Down 7.8 %

Shares of X4 Pharmaceuticals stock opened at $0.25 on Monday. The firm has a market cap of $43.42 million, a PE ratio of -2.78 and a beta of 0.39. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a fifty-two week low of $0.24 and a fifty-two week high of $1.60. The business’s fifty day moving average is $0.43 and its two-hundred day moving average is $0.52.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.43 million for the quarter, compared to analyst estimates of $1.07 million.

Insider Activity

In other news, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the transaction, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. The trade was a 6.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 202,663 shares of company stock valued at $91,198 in the last ninety days. Company insiders own 1.62% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in XFOR. Point72 Asset Management L.P. grew its stake in shares of X4 Pharmaceuticals by 4.0% in the fourth quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock valued at $477,000 after buying an additional 24,948 shares in the last quarter. Deutsche Bank AG boosted its holdings in X4 Pharmaceuticals by 559.6% in the 4th quarter. Deutsche Bank AG now owns 267,628 shares of the company’s stock worth $195,000 after acquiring an additional 227,051 shares during the period. Cantor Fitzgerald L. P. acquired a new stake in X4 Pharmaceuticals in the fourth quarter valued at approximately $30,000. Bank of America Corp DE raised its stake in shares of X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after purchasing an additional 22,485 shares during the period. Finally, Acorn Capital Advisors LLC acquired a new position in shares of X4 Pharmaceuticals during the fourth quarter worth $5,363,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.